Skip to main content
. 2013 Oct 15;170(5):1137–1151. doi: 10.1111/bph.12367

Figure 9.

Figure 9

A working model illustrating the involvement of PTEN loss and the activation of Akt in the localization of ABCG2 to the cell surface in the resistant MCF-FLV1000 cells. While the aetiology for the dramatic decrease in PTEN expression in the resistant cells is still not clear, PPARγ agonist treatments were found to reverse the PTEN loss in the resistant cells, subsequently inhibiting Akt, and leading to the re-localization of ABCG2 from the cell surface to the cytoplasm.